Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Marina Biotech and Girindus Group have entered into a strategic alliance under which Girindus will have exclusive rights to develop, supply and commercialize certain oligonucleotide constructs using Marina's Conformationally Restricted Nucleotide (CRN) chemistry.
Subscribe to our email newsletter
In return, Marina will receive royalties from the sale of CRN-based oligonucleotide reagents as well as a robust supply of cGMP material for Marina and its partners’ pre-clinical, clinical and commercialization needs.
CRN technology provides a direct means of developing highly potent and specific oligonucleotide-based therapeutics to target messenger RNAs or microRNAs.
Girindus America CEO and Girindus AG vorstand Marc Lemaitre said the alliance allows the comapny to develop and exploit, to the benefit of the customers, both the solid-phase technology platform related to oligonucleotides and a wide array of established solution-phase chemistries.
"We have decided to enter into this alliance with Marina because we believe its proprietary CRN chemistry provides unique benefits to oligonucleotide constructs, and offers a new research and development tool to the field of nucleic acid based therapeutics," Lemaitre added.
Girindus provides oligonucleotide development and manufacturing services, with related analytical and regulatory support, as well as apply small molecule chemistry to both amidites and oligonucleotide modifications.